Wave Life Sciences Ltd.
Wave Life Sciences Reports Q4 2024 Financial Results and Business Updates
Summary
Wave Life Sciences Ltd. reported financial results for Q4 and full year 2024, showing a net income of $29.3 million in Q4 2024 compared to a net loss of $16.3 million in Q4 2023. The company highlighted clinical progress across its pipeline, with enrollment completed in the first single dose cohort of the INLIGHT trial for obesity, multi-dosing ongoing in the 200 mg cohort of the RestorAATion-2 trial for AATD, and positive interim results from the FORWARD-53 trial for DMD. Wave expects to deliver clinical data from INLIGHT in the second half of 2025 and 48-week data from FORWARD-53 and feedback from regulators in 1Q 2025. The company also announced an expected IND submission for WVE-003 in Huntington's disease in the second half of 2025. Wave had cash and cash equivalents of $302.1 million as of December 31, 2024, with a runway expected into 2027.
Get alerts for WVE
Be first to know when Wave Life Sciences Ltd. files with the SEC.
Filing Categories
Exhibits (2)
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a biotechnology company engaged in the research and development of stereopure nucleic acid therapies. The primary focus of Wave Life Sciences is to leverage its unique platform to design and optimize therapies that modulate RNA to address genetic diseases. This involves developing treatments with high specificity and efficacy, potentially offering advantages over traditional nucleic acid therapies. The company targets a range of serious diseases, including those related to the central nervous system, with its innovative therapies. Wave Life Sciences plays a significant role in the biopharmaceutical industry by expanding the potential of gene medicine. Its work has implications for sectors such as healthcare and pharmaceuticals, especially in developing new treatment modalities for unmet medical needs. The company's research and development efforts are geared towards delivering transformational outcomes for patients, positioning it as a pioneer in the evolving field of genetic medicine. Wave Life Sciences Ltd. claims a critical space within the market for its advancements in precision medicine and continues to collaborate with various stakeholders to push the boundaries of therapeutic development.
Official SEC Documents